Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.

Xinru DengChenhong ZhangPengxu WangWei WeiXiaoyang ShiPingping WangJunpeng YangLimin WangShasha TangYuanyuan FangYalei LiuYiqi ChenYun ZhangQian YuanJing ShangQuane KanHuihui YangHua ManDanyu WangHuijuan Yuan

Published in: The Journal of clinical endocrinology and metabolism (2022)

Empagliflozin may be a superior initial therapy for patients with T2DM at risk of CVDs; its cardiovascular benefits may be associated with shifts in gut microbiota and plasma metabolites.

Keyphrases

type diabetes
ms ms
glycemic control
cardiovascular disease
skeletal muscle
weight loss